<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>前免疫</title><link/>https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%20%5BNLMID%5D&amp;utm_medium = rsss＆utm_campaig n =期刊＆v = 2.18.0.post9+e462414＆fc = none＆ff = 20250312141510＆utm_source = chrome＆utm_content = 101560960<description>前免疫：PubMed的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/?sort=date&amp;term=101560960%20%5BNLMID%5D&amp;utm_medium=rss&amp;utm_campaign=journals&amp;v=2.18.0.post9+e462414&amp;fc=None&amp;ff=20250312141510&amp;utm_source=Chrome&amp;utm_content=101560960" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS提要（2.18.0.post9+E462414）</generator><language> en</language><lastbuilddate> 2025年3月12日，星期三18:15:11 +0000</lastbuilddate><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title> PKR调节无菌全身性炎症触发的神经炎症和脑葡萄糖代谢障碍</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070845/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>无菌全身性炎症可能有助于神经炎症并加速神经退行性疾病的进展。双链RNA依赖性蛋白激酶（PKR）是一个关键信号分子，通过调节巨噬细胞激活，各种炎症途径和炎症体形成来调节免疫反应。这项研究旨在研究PKR在调节无菌全身性炎症触发的神经炎症和认知功能障碍中的作用。在这里，剖腹手术... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1469737。 doi：10.3389/fimmu.2025.1469737。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">无菌全身性炎症可能有助于神经炎症并加速神经退行性疾病的进展。双链RNA依赖性蛋白激酶（PKR）是一个关键信号分子，通过调节巨噬细胞激活，各种炎症途径和炎症体形成来调节免疫反应。这项研究旨在研究PKR在调节无菌全身性炎症触发的神经炎症和认知功能障碍中的作用。在这里，使用无菌全身性炎症触发的剖腹手术小鼠模型研究神经免疫反应。我们的研究表明，在小鼠中，PKR的遗传缺失有效地减弱了剖腹手术引起的周围和神经炎症和认知缺陷。此外，脑室内注射RAAV-DIO-PKR-K296R抑制CHAT-IRES-CRE-CRE-EGFP小鼠的胆碱能神经元的PKR，从而挽救了腹腔切开术引起的脑葡萄糖代谢的关键代谢产物的关键代谢物的变化，尤其是在磷酸化代谢方面的变化，并在磷酸化代谢方面的变化，以及磷酸化的含量变化，以及磷酸化和磷酸化的变化。空间工作记忆。我们的结果表明，PKR在调节神经炎症，脑葡萄糖代谢和认知功能障碍中的关键作用。 PKR可能是治疗系统性炎症诱导的神经炎症和认知功能障碍的新型药理靶标。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070845/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070845</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893411/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893411</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1469737>10.3389/fimmu.2025.1469737</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070845</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Wai-Yin Cheng</dc:creator><dc:creator> Xin-Zin Lee</dc:creator><dc:creator> Michael Siu-Lun Lai</dc:creator><dc:creator> Yuen-Shan Ho</dc:creator><dc:creator> Raymond Chuen-Chung Chang</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>PKR调节无菌全身性炎症触发的神经炎症和脑葡萄糖代谢障碍</dc:title><dc:identifier>PMID：40070845</dc:identifier><dc:identifier> PMC：PMC11893411</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1469737</dc:identifier></item><item><title>血清蛋白质组学通过跟踪SARS-COV-2杂交免疫力来揭示高亲和力和收敛抗体</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070844/?utm_source = chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description> SARS-COV-2及其对人类健康的持续影响的迅速传播促使单克隆抗体疗法的有效和快速发展。在这项研究中，我们研究了三个具有SARS-COV-2免疫的供体的血清和B细胞中的多克隆抗体，以找到高亲和力抗SARS-COV-2抗体以逃避变异。血清IgG抗体是通过对受体结合结构域（RBD）和非RBD位点的亲和力选择的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1509888。 doi：10.3389/fimmu.2025.1509888。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> SARS-COV-2及其对人类健康的持续影响的迅速传播促使单克隆抗体疗法的有效和快速发展。在这项研究中，我们研究了三个具有SARS-COV-2免疫的供体的血清和B细胞中的多克隆抗体，以找到高亲和力抗SARS-COV-2抗体以逃避变异。血清IgG抗体是通过对Omicron subvariant B.1.1.529的尖峰蛋白上的受体结合结构域（RBD）和非RBD位点的亲和力选择的。通过自下而上的质谱法分析抗体，并与每个供体的单核和散装测序曲目匹配。重组表达在血清中观察到的抗体，并表征以评估域结合，不同变体之间的交叉反应性以及抑制RBD结合到宿主蛋白的能力。感染早期Omicron子变量的供体具有与RBD的亚摩尔亲和力的血清抗体，该抗体也显示出与较新的Omicron子体相变BQ.1.1的结合活性。供体还显示了收敛的免疫反应。血清抗体和其他单细胞序列与公开报道的抗SARS-COV-2抗体相似，而特征的血清抗体具有与报道的公共序列相同的变体结合和中和曲线。分析的血清抗体是B细胞库中抗SARS-COV-2抗体的一个子集，该抗体表现出B细胞之间的显着动力学和外周血中循环抗体的显着动力学。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070844/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070844</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893383/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893383</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1509888>10.3389/fimmu.2025.1509888</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070844</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator>阿南德·帕特尔</dc:creator><dc:creator>Thiago Lima</dc:creator><dc:creator>理查德·卡森（Richard Carson）</dc:creator><dc:creator> Qiulong Huang</dc:creator><dc:creator> Stefano R Bonissone</dc:creator><dc:creator>娜塔莉·卡斯特拉纳（Natalie Castellana）</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>血清蛋白质组学通过跟踪SARS-COV-2杂交免疫力来揭示高亲和力和收敛抗体</dc:title><dc:identifier>PMID：40070844</dc:identifier><dc:identifier> PMC：PMC11893383</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1509888</dc:identifier></item><item><title>对肠道微生物群的新兴见解是免疫的关键调节剂和对肝细胞癌免疫疗法的反应</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070843/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>肠道微生物群是一种通过门静脉与肝脏紧密相关的复杂微生物生态系统，已成为肝脏健康和疾病的关键调节剂。许多研究强调了其在肝病的发作和进展中的作用，包括酒精性肝病，代谢功能障碍相关的脂肪分裂肝病（MASLD），代谢功能障碍相关的脂肪性肝炎（MASH），肝纤维化，cir纤维化，cirrhosis，cirrhosis，and Cirrhhosis，和Hepatocellarlular carcinallular carcincinomal（HCC）。这篇评论提供了... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1526967。 doi：10.3389/fimmu.2025.1526967。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">肠道微生物群是一种通过门静脉与肝脏紧密相关的复杂微生物生态系统，已成为肝脏健康和疾病的关键调节剂。许多研究强调了其在肝病的发作和进展中的作用，包括酒精性肝病，代谢功能障碍相关的脂肪分裂肝病（MASLD），代谢功能障碍相关的脂肪性肝炎（MASH），肝纤维化，cir纤维化，cirrhosis，cirrhosis，and Cirrhhosis，和Hepatocellarlular carcinallular carcincinomal（HCC）。这篇综述概述了当前对肠道微生物群对HCC进展的影响的见解，尤其是其对HCC肿瘤微环境（TME）中免疫细胞的影响。此外，我们探讨了肠道菌群靶向的干预措施，例如抗生素，益生菌，益生元和粪便菌群移植（FMT），以调节HCC中免疫疗法的免疫反应并改善免疫疗法的预后。通过综合最近的研究的见解，该评论的目的是强调基于微生物群的策略，这些策略可能会增强免疫疗法结果，从而推进HCC治疗中的个性化方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070843/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070843</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893557/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893557</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1526967>10.3389/fimmu.2025.1526967</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070843</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Siqi Ren</dc:creator><dc:creator> Zhang</dc:creator><dc:creator> Xingyue Wang</dc:creator><dc:creator> Jiahong su</dc:creator><dc:creator>徐王</dc:creator><dc:creator>Zijun Yuan</dc:creator><dc:creator> Xinyu He</dc:creator><dc:creator>虹吸</dc:creator><dc:creator>chen</dc:creator><dc:creator> Shuai Deng</dc:creator><dc:creator> Xu Wu</dc:creator><dc:creator> mingxing li</dc:creator><dc:creator>福克恩·杜（Fukuan du）</dc:creator><dc:creator> Yueshui Zhao</dc:creator><dc:creator> Jing Shen</dc:creator><dc:creator>魏胡</dc:creator><dc:creator>小li</dc:creator><dc:creator> Zhangang Xiao</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>对肠道微生物群的新兴见解是免疫的关键调节剂和对肝细胞癌免疫疗法的反应</dc:title><dc:identifier>PMID：40070843</dc:identifier><dc:identifier> PMC：PMC11893557</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1526967</dc:identifier></item><item><title>基于130,518个注册干细胞供体的八个印度人群的HLA等位基因和单倍型频率</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070842/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>简介：在造血干细胞移植中，当与人类白细胞抗原（HLA）基因相匹配时，将获得最佳结果。人群特异性的HLA等位基因和单倍型频率分布确定了在给定大小和种族组成的干细胞供体注册表中找到匹配供体的概率。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1528177。 doi：10.3389/fimmu.2025.1528177。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">简介：在造血干细胞移植中，当与人类白细胞抗原（HLA）基因相匹配时，将获得最佳结果。人群特异性的HLA等位基因和单倍型频率分布确定了在给定大小和种族组成的干细胞供体注册表中找到匹配供体的概率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：为了评估印度患者对未来捐助者的需求，我们分析了大量<i>n</i> = 130,518个潜在的干细胞捐赠者DKMS-BMST的数据集，DKMS-BMST是一项总部位于班加罗尔的捐助者注册表，并在全国范围内供体招聘活动。我们通过母语和父母的起源状态定义了8种亚群。该亚种群包括四个属于德拉维亚语言家族的样本（母语：卡纳达语/起源州：卡纳塔克邦：卡纳塔克邦，泰米尔语/泰米尔纳德邦，泰卢固语/安德拉邦和马拉雅拉姆邦和马拉雅拉姆语/喀拉拉邦），以及四个属于印度 - 玛丽亚语言的样本邦，马拉地语/马哈拉施特拉邦）。亚种群和大型样本量的确切定义在<i>n</i> = 5,808（泰卢固语/安得拉邦）和<i>n</i> = 14,866（马拉雅拉姆语/喀拉拉邦）之间的确切定义是我们研究的优势。我们有关HLA等位基因和单倍型频率的结果完善了已发布的数据。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果与讨论：就遗传相关性而言，我们观察到亚种群分为南部和西北部的印度群集和孟加拉/西孟加拉邦样本，这与其他七个亚群差异很大。印度南部人口的患者是当前种族组成中DKMS-BMST注册中心的主要受益者。随着印度不同地区的当地招聘办公室的开设，将来将在全国范围内实现更加全国范围的报道。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070842/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070842</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893841/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893841</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1528177>10.3389/fimmu.2025.1528177</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070842</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Ute v Solloch</dc:creator><dc:creator> Chinma Kaniyath Madhusoodhanan</dc:creator><dc:creator> Vinzenz Lange</dc:creator><dc:creator> JürgenSauter</dc:creator><dc:creator> Latha Jagannathan</dc:creator><dc:creator>帕特里克·保罗</dc:creator><dc:creator>Marcelo afernández-Viña</dc:creator><dc:creator>亚历山大·H·施密特（Alexander H Schmidt）</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>基于130,518个注册干细胞供体的八个印度人群的HLA等位基因和单倍型频率</dc:title><dc:identifier>PMID：40070842</dc:identifier><dc:identifier> PMC：PMC11893841</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1528177</dc:identifier></item><item><title>通过溶瘤病毒表达SIRPα-FC的表达可通过肿瘤微环境重编程增强抗肿瘤功效</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070841/?utm_source = chrome&amp;utm_medium = rsss＆utm_camp aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>溶瘤病毒（OVS）在肿瘤中有选择地复制，直接杀死癌细胞，并通过释放肿瘤抗原促进全身免疫反应。这些功能使OVS成为肿瘤免疫疗法的有前途的方法，提供了较少副作用的靶向治疗方法。尽管有这些优势，但OV主要是通过肿瘤内注射来给药，从而限制了它们对晚期，系统性癌症的有效性。在OV中，溶瘤腺病毒（OADV）是最广泛的研究... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1513555。 doi：10.3389/fimmu.2025.1513555。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">溶瘤病毒（OVS）在肿瘤中有选择地复制，直接杀死癌细胞，并通过释放肿瘤抗原促进全身免疫反应。这些功能使OVS成为肿瘤免疫疗法的有前途的方法，提供了较少副作用的靶向治疗方法。尽管有这些优势，但OV主要是通过肿瘤内注射来给药，从而限制了它们对晚期，系统性癌症的有效性。在OV中，由于良好的基因调节，安全性和稳定性，癌腺病毒（OADV）是最广泛研究的。在这项研究中，经过改进的OADV载体PDC316-OAD-SA，设计用于表达SIRPα-MIGG1FC基因，该基因旨在重塑与肿瘤相关的巨噬细胞（TAMS）并增强抗肿瘤免疫力。<i>在体外</i>和<i>体内</i>评估了该载体以及对照病毒（AD-ON）。修饰的OAD-SA显着改善了巨噬细胞吞噬作用，并在鼠模型中显示出较高的肿瘤消退。此外，尽管两种OADV都会增加T细胞微环境中T细胞的浸润，但OAD-SA特异性增强了T细胞免疫功能。该研究还表明，OADV在肿瘤类型的各种类型中调节TAM，OAD-SA治疗尤其增加了TAM吞噬作用并促进抗肿瘤反应。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070841/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070841</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893986/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893986</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1513555>10.3389/fimmu.2025.1513555</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070841</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator>青杨</dc:creator><dc:creator>杨舒</dc:creator><dc:creator>Yanwei Chen</dc:creator><dc:creator> Zhongbing气</dc:creator><dc:creator>Shichuan Hu</dc:creator><dc:creator>张张</dc:creator><dc:creator>YU QIN</dc:creator><dc:creator> Xianglin Xu</dc:creator><dc:creator> Jianchuan Hu</dc:creator><dc:creator> Anliang Huang</dc:creator><dc:creator>平郑</dc:creator><dc:date>2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>通过溶瘤病毒表达SIRPα-FC的表达可通过肿瘤微环境重编程增强抗肿瘤功效</dc:title><dc:identifier>PMID：40070841</dc:identifier><dc:identifier> PMC：PMC11893986</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1513555</dc:identifier></item><item><title>通过机器学习和实验分析，在动脉粥样硬化中鉴定脂质代谢相关的免疫标记物</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070840/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>结论：我们的研究介绍了与动脉粥样硬化有关的新型脂质代谢相关诊断标志物，并强调它们作为免疫相关药物靶标的潜力。这项研究为预测​​诊断和针对性治疗动脉粥样硬化提供了一种宝贵的方法。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1549150。 doi：10.3389/fimmu.2025.1549150。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：动脉粥样硬化是导致心血管疾病的重要原因，而常规诊断方法在及时，准确地检测早期动脉粥样硬化中经常缺乏。异常脂质代谢在动脉粥样硬化的发展中起着至关重要的作用。因此，新诊断标记的识别对于精确诊断该病情至关重要。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：在本研究中使用的与动脉粥样硬化有关的数据集获自GEO数据库（GSE2470，GSE24495，GSE100927和GSE43292）。 SSGSEA技术首先用于评估受动脉粥样硬化影响的样品中的脂质代谢评分，从而有助于发现通过WGCNA与脂质代谢相关的重要调节基因。此后，进行了差异表达分析和功能评估，之后采用各种机器学习方法来确定动脉粥样硬化的重要诊断基因。然后通过多种机器学习算法开发并验证了诊断模型。此外，进行了分子对接研究，以分析这些关键标记与治疗剂对动脉粥样硬化的结合亲和力。 SSGSEA技术还用于测量动脉粥样硬化样品中的免疫细胞评分，可帮助探索关键诊断标记与免疫细胞之间的联系。最后，通过实验验证证实了所鉴定的关键基因的表达变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：WGCNA在动脉粥样硬化样品中鉴定了302个与脂质代谢相关的基因，功能分析表明，这些基因与多种免疫途径有关。通过使用机器学习算法进行进一步的差分分析和筛选，APLNR，PCDH12，PODXL，SLC40A1，TM4SF18和TNFRSF25被鉴定为动脉粥样硬化的关键诊断基因。确认我们构建的诊断模型以高精度预测动脉粥样硬化的发生，分子对接研究表明，这六个关键的诊断基因具有潜力作为药物靶标。另外，SSGSEA算法进一步验证了这些诊断基因与各种免疫细胞的关联。最后，实验证实了这六个基因的表达水平。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：我们的研究介绍了与动脉粥样硬化有关的新型脂质代谢相关诊断标志物，并强调它们作为免疫相关药物靶标的潜力。这项研究为预测​​诊断和针对性治疗动脉粥样硬化提供了一种宝贵的方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070840/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070840</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893410/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893410</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1549150>10.3389/fimmu.2025.1549150</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070840</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator>挂陈</dc:creator><dc:creator>Biao Wu</dc:creator><dc:creator> Kunyu Guan</dc:creator><dc:creator> Liang Chen</dc:creator><dc:creator> Kangjie Chai</dc:creator><dc:creator> Maoji Ying</dc:creator><dc:creator> dazhi li</dc:creator><dc:creator> Zhae</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>通过机器学习和实验分析，在动脉粥样硬化中鉴定脂质代谢相关的免疫标记物</dc:title><dc:identifier>PMID：40070840</dc:identifier><dc:identifier> PMC：PMC11893410</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1549150</dc:identifier></item><item><title> PD-1/PD-L1抑制剂的功效和安全性或在转移性或晚期肾细胞癌治疗中的功效和安全性：网络荟萃分析</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070839/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>结论：使用PD-1/PD-L1抑制剂或组合中，在治疗转移性或晚期RCC方面发现了良好的功效，在RCC患者中显着改善和增强了OS，PFS，ORR，ORR，CR，PR和DCR。患者不良反应的发生率没有增加，不良反应是可控制的。这些发现表明，PD-1/PD-L1抑制剂的单一或联合使用在转移或晚期RCC治疗方面表现出良好的功效和安全性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1524497。 doi：10.3389/fimmu.2025.1524497。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：这项研究系统地回顾了编程因子1（PD-1）/编程因子1配体（PD-L1）抑制剂的单一或联合使用的功效和安全性，以治疗转移性或晚期肾细胞癌（RCC）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：通过搜索PubMed，Web of Science，Embase，Cochrane库和临床试验以及相关的随机对照实验，收集了相关文章进行荟萃分析。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：根据11项研究，在总生存期（OS）[r = 0.74，95％CI：0.69〜0.80， <i>p</i> &lt;0.00001]，无进展生存率（PFS）[HR = 0.68，95％CI：0.68，95％CI：0.57 〜0.801， <i>PFS</i> ），（pfs），无效的生存率（PFS），显着高于对照组的有效性。 [RR=1.71, 95%CI: 1.39~2.12, <i>P</i> &lt;0.00001], complete response rate (CR) [RR=2.99 95%CI: 2.34~3.83, <i>P</i> &lt;0.0001], partial response rate (PR) [RR=1.56, 95%CI: 1.20~2.01, <i>P</i> =0.001], and disease control rate (DCR) [RR=1.13, 95％CI：1.06〜1.20， <i>p</i> &lt;0.0001]。 No statistical significance was observed between the experimental and control groups in overall adverse reactions (AEs) [RR=1.01, 95%CI: 0.98~1.04, <i>P</i> =0.598], the incidence of stage I~II adverse reactions [RR=1.02, 95%CI: 0.88~1.17, <i>P</i> =0.818], or stage III~V adverse reactions [RR=0.98, 95％CI：0.81〜1.18， <i>p</i> = 0.817]。关于亚组分析，实验组中吞咽困难，皮疹，甲状腺功能低下和瘙痒的发生率显着高于对照组。与对照组相比，实验组的腹泻，恶心，消化不良和疲劳的发生率在统计学上不显着。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：使用PD-1/PD-L1抑制剂或组合中，在治疗转移性或晚期RCC方面发现了良好的功效，在RCC患者中显着改善和增强了OS，PFS，ORR，ORR，CR，PR和DCR。患者不良反应的发生率没有增加，不良反应是可控制的。这些发现表明，PD-1/PD-L1抑制剂的单一或联合使用在转移或晚期RCC治疗方面表现出良好的功效和安全性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070839/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070839</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893867/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893867</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1524497>10.3389/fimmu.2025.1524497</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070839</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Dongli Zhang</dc:creator><dc:creator>郑阴</dc:creator><dc:creator>Weichuan Zhang</dc:creator><dc:creator> Haibin Chen</dc:creator><dc:creator> Jianjun Zhao</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>PD-1/PD-L1抑制剂的功效和安全性或在转移性或晚期肾细胞癌治疗中的功效和安全性：网络荟萃分析</dc:title><dc:identifier>PMID：40070839</dc:identifier><dc:identifier> PMC：PMC11893867</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1524497</dc:identifier></item><item><title>使用双屈服微局部测定法对血清抗体反应的深入免疫化学表征</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070838/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>抗原特异性的体液免疫可以通过分析血清抗体的分析来表征。尽管可以使用用于测量特定抗体水平的血清学测定法，但在生化意义上并不是定量的。但是，在系统水平上定量地了解体液免疫反应将需要一种普遍，完整，定量，可比较的测量方法，用于选定免疫球蛋白类别的抗原特异性血清抗体。在这里，我们描述了荧光，... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1494624。 doi：10.3389/fimmu.2025.1494624。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">抗原特异性的体液免疫可以通过分析血清抗体的分析来表征。尽管可以使用用于测量特定抗体水平的血清学测定法，但在生化意义上并不是定量的。但是，在系统水平上定量地了解体液免疫反应将需要一种普遍，完整，定量，可比较的测量方法，用于选定免疫球蛋白类别的抗原特异性血清抗体。在这里，我们描述了一种荧光，双硝化免疫测定法，它提供了生化参数，这些参数既是必要且足以定量表征体液免疫反应的必要且足够的参数。为了验证理论，我们使用了SARS-COV-2的重组受体结合结构域作为微司托阵列上的抗原，并改变了受感染者的抗原和血清抗体的浓度，以获得结合数据的测量矩阵。两种滴定曲线均使用基于广义逻辑函数的算法同时拟合，并适用于分析结合的生化变量。我们获得了不同抗体类别的平衡亲和力常数和浓度。这些变量分别反映了血清抗体的质量和有效量。拟议的荧光双屈服微司分免疫测定可以生成真正适合免疫，医学和系统生物学分析的定量血清学数据。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070838/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070838</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893856/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893856</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1494624>10.3389/fimmu.2025.1494624</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070838</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> ÁgnesKovács</dc:creator><dc:creator> ZoltánHérincs</dc:creator><dc:creator> KrisztiánPapp</dc:creator><dc:creator> Jakub Zbigniew Kaczmarek</dc:creator><dc:creator>丹尼尔·尼伯格·拉尔森（Daniel Nyberg Larsen）</dc:creator><dc:creator> Pernille舞台</dc:creator><dc:creator>LászlóBereczki</dc:creator><dc:creator> Eszter Ujhelyi</dc:creator><dc:creator>塔玛斯·菲尔（TamásPfeil）</dc:creator><dc:creator> JózsefPrechl</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>使用双屈服微局部测定法对血清抗体反应的深入免疫化学表征</dc:title><dc:identifier>PMID：40070838</dc:identifier><dc:identifier> PMC：PMC11893856</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1494624</dc:identifier></item><item><title>地塞米松对猪血清细胞的能量代谢有深远的影响，并防止LPS诱导的糖酵解开关</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070837/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>在农场动物中，对免疫细胞的能量代谢与其激活状态之间的关系知之甚少。此外，最近有证据表明，某种强大的基于糖皮质激素的药物地塞米松可以通过干扰免疫细胞的能量代谢来发挥其抗炎作用，但这些机制尚未完全了解。为了解决这些知识差距，我们探索了猪外周血的能量代谢之间的联系... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1514061。 doi：10.3389/fimmu.2025.1514061。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">在农场动物中，对免疫细胞的能量代谢与其激活状态之间的关系知之甚少。此外，最近有证据表明，某种强大的基于糖皮质激素的药物地塞米松可以通过干扰免疫细胞的能量代谢来发挥其抗炎作用，但这些机制尚未完全了解。为了解决这些知识差距，我们探讨了猪外周血单核细胞（PBMC）的能量代谢与它们对脂多糖（LPS）（LPS）和<i>地</i>塞米松（Dex）的反应刺激的反应。 PBMC与糖酵解抑制剂2-脱氧-D-葡萄糖或HIF-1α抑制剂KC7F2的代谢进行干预降低了LPS诱导的TNF-α产生，但是线粒体ATP ATP合成抑制剂糖尿病没有显着影响。 DEX的抗炎作用不受任何抑制剂的影响。为了研究LPS和DEX在PBMC中的代谢作用，我们使用Seahorse XFE96 Flux Analyzer评估了24小时刺激后的糖酵解和线粒体呼吸。我们的结果表明，在LPS处理的PBMC中，糖酵解明显更高，但没有提供有关线粒体呼吸发生变化的证据。相反，DEX降低了LPS诱导的糖酵解，尤其是单独给药时，线粒体呼吸显着降低。用KC7F2进行预处理抵消了LP和DEX对糖酵解的影响，并且无论PBMC的炎症状态如何，线粒体呼吸降低。基因表达分析鉴定出葡萄糖转运蛋白<i>SLC2A3</i> ，三羧酸循环基因<i>IDH1</i>和<i>SDHB</i>是LPS和DEX的拮抗代谢作用的主要开关，与PBMC的炎症状态密切相关。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070837/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070837</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893826/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893826</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1514061>10.3389/fimmu.2025.1514061</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070837</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Wenjuan MA</dc:creator><dc:creator>朱莉娅·布伦莫尔（Julia Brenmoehl）</dc:creator><dc:creator> Nares Trakooljul</dc:creator><dc:creator>克劳斯·威默斯（Klaus Wimmers）</dc:creator><dc:creator>爱德华·穆拉尼（Eduard Murani）</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>地塞米松对猪血清细胞的能量代谢有深远的影响，并防止LPS诱导的糖酵解开关</dc:title><dc:identifier>PMID：40070837</dc:identifier><dc:identifier> PMC：PMC11893826</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1514061</dc:identifier></item><item><title> B7-H3和LAG3的共表达代表人类中CD4 &lt;sup>;+&lt;/sup>; T细胞的细胞毒性</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070836/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>最近的研究强调了CD4^（+）T细胞具有细胞毒性活性（CD4 CTL）对抗肿瘤免疫的潜在贡献。然而，它们的确切作用仍然难以捉摸，部分原因是缺乏定义人类中具有目标杀伤潜力的CD4 CTL的特定标记。我们先前证明了爱泼斯坦 - 巴尔病毒（EBV）驱动的永生B细胞系有效地诱导人类CD4 CTL，具有与细胞毒性CD8^（+）T细胞（CD8 CTLS）相当的细胞毒性功能。我们在这里显示... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1560383。 doi：10.3389/fimmu.2025.1560383。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">最近的研究强调了CD4 <sup>+</sup> T细胞具有细胞毒性活性（CD4 CTL）对抗肿瘤免疫的潜在贡献。然而，它们的确切作用仍然难以捉摸，部分原因是缺乏定义人类中具有目标杀伤潜力的CD4 CTL的特定标记。我们先前证明了爱泼斯坦 - 巴尔病毒（EBV）驱动的永生B细胞系有效地诱导人类CD4 CTL，具有与细胞毒性CD8 <sup>+</sup> T细胞相当的细胞毒性功能（CD8 CTL）。在这里，我们表明，EBV驱动的CD4 CTL与CD8 CTL相比表现出长时间的增殖和持续的细胞毒性，尽管它们的细胞毒性功能在长期培养过程中明显降低。具有不同细胞毒性活性的CD4 CTL的比较转录组分析将B7-H3和LAG3鉴定为与高度细胞毒性CD4 CTL相关的表面分子。 B7-H3和LAG3的共表达与CD107A的表达相关，并在CD4 <sup>+</sup> T细胞上观察到具有靶向依赖性的细胞毒性潜能的CD4 + T细胞，但在CD8 CTL上观察到。此外，B7-H3 <sup>+</sup> LAG3 <sup>+</sup> CD4 <sup>+</sup> T细胞在与B细胞急性淋巴细胞性白血病（B-ALL）的小儿患者的骨髓细胞共培养过程中。这些发现表明，B7-H3和LAG3共表达代表了人类功能性CD4 CTL的特征，从而提供了对CD4 CTL在肿瘤免疫中的作用的宝贵见解。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/40070836/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070836</a> | PMC： <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893609/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893609</a> | doi： <a href=https://doi.org/10.3389/fimmu.2025.1560383>10.3389/fimmu.2025.1560383</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> PubMed：40070836</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Yumi Tamura</dc:creator><dc:creator> Shun Ohki</dc:creator><dc:creator> Haruna Nagai</dc:creator><dc:creator> Rin Yoshizato</dc:creator><dc:creator> Shizuki Nishi</dc:creator><dc:creator> Yuqi Jin</dc:creator><dc:creator> Yasuo Kitajima</dc:creator><dc:creator> Yun Guo</dc:creator><dc:creator> Tatsuo Ichinohe</dc:creator><dc:creator> Satoshi冈田</dc:creator><dc:creator>Yohei Kawano</dc:creator><dc:creator> Tomoharu Yasuda</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>B7-H3和LAG3的共表达代表人类中CD4 &lt;sup>;+&lt;/sup>; T细胞的细胞毒性</dc:title><dc:identifier>PMID：40070836</dc:identifier><dc:identifier> PMC：PMC11893609</dc:identifier><dc:identifier> doi：10.3389/fimmu.2025.1560383</dc:identifier></item><item><title>急性智力肝衰竭中嗜中性粒细胞相关的生物标志物的鉴定和验证</title><link/>https://pubmed.ncbi.nlm.nih.gov/40070835/？ aign =期刊＆utm_content = 101560960＆fc = none＆ff = 20250312141510＆v = 2.18.0.post9+e462414<description>外周血中性粒细胞功能障碍发生在急性智力肝衰竭（ACLF）中。然而，参与ACLF的病理生理学的中性粒细胞的分子机制仍然鲜为人知。从GEO数据库（GSE142255）下载的数据用于借助Limma软件包和加权基因共表达网络分析（WGCNA）算法识别ACLF和中性粒细胞相关的基因。该分析确定了288个ACLF相关差异表达的基因... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025年2月25日； 16：1477342。 doi：10.3389/fimmu.2025.1477342。环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">外周血中性粒细胞功能障碍发生在急性智力肝衰竭（ACLF）中。然而，参与ACLF的病理生理学的中性粒细胞的分子机制仍然鲜为人知。从GEO数据库（GSE142255）下载的数据用于借助Limma软件包和加权基因共表达网络分析（WGCNA）算法识别ACLF和中性粒细胞相关的基因。该分析确定了循环血细胞中288个与ACLF相关的差异表达基因（DEG）。其中，发现三个基因与嗜中性粒细胞有关，并被鉴定为诊断基因，表现出很高的诊断功效，如曲线下的面积（AUC）值为1所证明的。在这些面积（AUC）值为1。与健康对照组相比，ACLF患者的循环免疫细胞中（CCL5）被下调。这些发现使用额外的GEO数据集GSE156382证实了这些发现。三个关键基因的表达水平表明与铁凋亡和库培症既有相关性。 Among the three diagnostic genes, only MMP9 was validated as differentially expressed through both quantitative real-time PCR (qRT-PCR) and western blot. Moreover, a significant elevation in plasma MMP9 levels was observed in patients with ACLF compared to those with chronic hepatitis B (CHB) and acute decompensated cirrhosis (AD). Notably, ACLF patients exhibiting elevated MMP9 levels (>;175.8 ng/mL) experienced higher short-term mortality rates within both 30 and 90 days (p&lt;0.001). In addition, a total of 21 drugs targeting the three diagnostic genes were identified from the Drug Bank database. Finally, the Kinase-TF-mRNA-miRNA network was constructed utilizing Cytoscape software. This study represents the initial application of WGCNA algorithms to identify novel biomarkers related to neutrophils in ACLF. Our findings offer new perspectives on the role of neutrophil in the pathogenesis of ACLF. However, additional research is required to substantiate the effects of these key genes and therapeutic agents on ACLF.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40070835/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070835</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893565/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893565</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1477342>10.3389/fimmu.2025.1477342</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40070835</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Wei Lin</dc:creator><dc:creator> Yongping Chen</dc:creator><dc:creator> Mingqin Lu</dc:creator><dc:creator> Cheng Peng</dc:creator><dc:creator> Xiang Chen</dc:creator><dc:creator> Xiaoqin Liu</dc:creator><dc:creator> Yunyun Wang</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>Identification and validation of neutrophil-related biomarkers in acute-on-chronic liver failure</dc:title><dc:identifier> pmid:40070835</dc:identifier><dc:identifier> pmc:PMC11893565</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1477342</dc:identifier></item><item><title> Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine</title><link/> https://pubmed.ncbi.nlm.nih.gov/40070834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250312141510&amp;v=2.18.0.post9+e462414<description> CONCLUSION: These data suggest that specific B-cell and T-cell responses could be sustained for at least one year after receiving the third vaccination. Our findings emphasize that the weak SARS-CoV-2-specific B-cell and T-cell responses induced in PLWH have implications for clinical decision-making and public health policy for PLWH with respect to SARS-CoV-2 infection. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Feb 25;16:1554409. doi: 10.3389/fimmu.2025.1554409.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: Both B-cell- and T-cell-mediated immunity are crucial for the effective clearance of viral infection, but little is known about the dynamic characteristics of SARS-CoV-2-specific B-cell and T-cell responses in people living with HIV (PLWH) after a full course of inactivated SARS-CoV-2 vaccination. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In this study, fifty people living with HIV (PLWH) and thirty healthy controls (HCs) were enrolled to assess B-cell and T-cell responses at the day before the vaccination (T0), two weeks after the first dose (T1), two months after the first dose (T2), the day of the third dose (T3), one month after the third dose (T4), three months after the third dose (T5) and 12 months (T6) after the third dose. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: SARS-CoV-2-specific B-cell and T-cell responses were induced in people living with HIV (PLWH), and these responses lasted at least one year after the third vaccine dose. However, the peak frequencies of Spike-specific B-cell and T-cell responses in PLWH were lower than those in HIV-negative controls. In addition, the expansion of activated B cells, memory B cells and plasma cells after primary vaccination was observed, but the percentages of these cells were decreased at T6 and were comparable to those at T0. Additionally, the percentages of activated T cells, exhausted T cells and SARS-CoV-2-specific T cells with enhanced functional activity were increased following the administration of inactivated SARS-CoV-2 vaccine. In addition, PLWH had lower percentages of plasma cells, RBD-specific B cells, circulating Tfh (cTfh) cells and CD38 <sup>+</sup> cTfh cells, and the percentages of the latter two types of cells were positively correlated with the titer of neutralizing antibodies, indicating these differences may account for the weaker immune responses induced in PLWH. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: These data suggest that specific B-cell and T-cell responses could be sustained for at least one year after receiving the third vaccination. Our findings emphasize that the weak SARS-CoV-2-specific B-cell and T-cell responses induced in PLWH have implications for clinical decision-making and public health policy for PLWH with respect to SARS-CoV-2 infection.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40070834/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070834</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893571/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893571</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1554409>10.3389/fimmu.2025.1554409</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40070834</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Xiuwen Wang</dc:creator><dc:creator> Xiaodong Yang</dc:creator><dc:creator> Xin Zhang</dc:creator><dc:creator> Hongxia Yan</dc:creator><dc:creator> Junyan Jin</dc:creator><dc:creator> Zhenglai Ma</dc:creator><dc:creator> Junyi Duan</dc:creator><dc:creator> Guanghui Zhang</dc:creator><dc:creator> Tao Huang</dc:creator><dc:creator> Yongzheng Li</dc:creator><dc:creator> hao Wu</dc:creator><dc:creator> Tong Zhang</dc:creator><dc:creator> Aiwei Zhu</dc:creator><dc:creator> Cong Jin</dc:creator><dc:creator> Xiangrong Song</dc:creator><dc:creator> bin su</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>Dynamic SARS-CoV-2-specific B-cell and T-cell responses induced in people living with HIV after a full course of inactivated SARS-CoV-2 vaccine</dc:title><dc:identifier> pmid:40070834</dc:identifier><dc:identifier> pmc:PMC11893571</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1554409</dc:identifier></item><item><title> Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review</title><link/> https://pubmed.ncbi.nlm.nih.gov/40070833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250312141510&amp;v=2.18.0.post9+e462414<description> Thyroid dysfunction is a common immune-related adverse event (irAE) associated with immune checkpoint inhibitors (ICIs) that target PD-1, PD-L1, and CTLA-4. Nevertheless, the incidence of severe cases, defined as grade 3 or higher, remains rare. This report presents a detailed case study of severe thyroiditis in a patient with non-small cell lung cancer (NSCLC) who developed grade 3 thyroiditis following a single cycle of sintilimab monotherapy. The clinical presentation in this patient was... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Feb 25;16:1548452. doi: 10.3389/fimmu.2025.1548452.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Thyroid dysfunction is a common immune-related adverse event (irAE) associated with immune checkpoint inhibitors (ICIs) that target PD-1, PD-L1, and CTLA-4. Nevertheless, the incidence of severe cases, defined as grade 3 or higher, remains rare. This report presents a detailed case study of severe thyroiditis in a patient with non-small cell lung cancer (NSCLC) who developed grade 3 thyroiditis following a single cycle of sintilimab monotherapy. The clinical presentation in this patient was remarkable for its early onset, occurring one week after the initiation of sintilimab therapy, and for its severe manifestations. During hospitalization, a prompt and accurate differential diagnosis was performed. Sintilimab treatment was discontinued, and the patient was promptly started on high-dose glucocorticoids, with a tapering schedule implemented as the condition improved or reached Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or lower. The patient subsequently developed overt hypothyroidism, necessitating the initiation of thyroxine replacement therapy. Furthermore, we provide a comprehensive review of the mechanisms and risk factors associated with thyroid dysfunction immune-related adverse events (TD-irAEs). It is imperative for clinicians to meticulously monitor the clinical symptoms exhibited by patients. For those presenting with symptoms, prompt diagnosis and appropriate symptomatic management are essential. Additionally, regular thyroid function testing is recommended for high-risk patients, and we advocate for the assessment of baseline levels of thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TGAb) prior to initiating ICI treatment.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40070833/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070833</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893825/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893825</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1548452>10.3389/fimmu.2025.1548452</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40070833</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Xiaolin Zhao</dc:creator><dc:creator> Xiaoyu Wang</dc:creator><dc:creator> Surui Liu</dc:creator><dc:creator> Pian Cheng</dc:creator><dc:creator> Jinjuan Chen</dc:creator><dc:creator> Jie Liu</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review</dc:title><dc:identifier> pmid:40070833</dc:identifier><dc:identifier> pmc:PMC11893825</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1548452</dc:identifier></item><item><title> &lt;em>;De Novo&lt;/em>; donor-specific anti-HLA antibody risk stratification in kidney transplantation using a combination of B cell and T cell molecular mismatch assessment</title><link/> https://pubmed.ncbi.nlm.nih.gov/40070832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250312141510&amp;v=2.18.0.post9+e462414<description> CONCLUSION: Our findings highlight the value of utilizing B cell and T cell epitope mismatch evaluation in living donor selection and immunological risk stratification to improve transplant outcomes. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Feb 25;16:1508796. doi: 10.3389/fimmu.2025.1508796.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> INTRODUCTION: The presence of <i>de novo</i> donor-specific antibody (dnDSA) has detrimental effect on allograft outcomes in kidney transplantation. As humoral responses in transplantation are elicited targeting non-self-epitopes on donor HLA proteins, assessing HLA mismatches at the molecular level provides a refined means for immunological risk stratification. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: In the present study, we utilized three HLA molecular mismatch assessment algorithms, Snow, HLAMatchmaker, and PIRCHE-II, to evaluate the independent and synergistic association of B cell and T cell epitope mismatches with dnDSA development in a cohort of 843 kidney transplant recipients. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Our results demonstrated that B cell and T cell epitope mismatches at HLA Class I and DRB1/DQB1 loci are remarkably increased in dnDSA-positive recipients, even after normalization by allele mismatch numbers in individual study subjects. Furthermore, elevated Snow, verified eplet mismatches, and PIRCHE-II scores are significantly associated with dnDSA occurrence individually and in combination. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION: Our findings highlight the value of utilizing B cell and T cell epitope mismatch evaluation in living donor selection and immunological risk stratification to improve transplant outcomes.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40070832/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070832</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893832/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893832</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1508796>10.3389/fimmu.2025.1508796</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40070832</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Elaine Chou-Wu</dc:creator><dc:creator> Matthias Niemann</dc:creator><dc:creator> Danny Youngs</dc:creator><dc:creator> Idoia Gimferrer</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>&lt;em>;De Novo&lt;/em>; donor-specific anti-HLA antibody risk stratification in kidney transplantation using a combination of B cell and T cell molecular mismatch assessment</dc:title><dc:identifier> pmid:40070832</dc:identifier><dc:identifier> pmc:PMC11893832</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1508796</dc:identifier></item><item><title> Case Report: Long-term suppression of relapses by dimethyl fumarate in a relapsing pediatric patient with myelin oligodendrocyte glycoprotein antibody-associated disease manifesting as acute disseminated encephalomyelitis, unilateral optic neuritis, and seizure episodes</title><link/> https://pubmed.ncbi.nlm.nih.gov/40070831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=journals&amp;utm_content=101560960&amp;fc=None&amp;ff=20250312141510&amp;v=2.18.0.post9+e462414<description> CONCLUSIONS: DMF showed long-term effects on suppressing relapses in a pediatric patient with MOGAD, revealing its potential as a treatment option for such patients. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>前免疫</b>。 2025 Feb 25;16:1551379. doi: 10.3389/fimmu.2025.1551379.环保2025。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated diseases (MOGAD), which has been recognized as a distinct entity in patients with neuromyelitis optica spectrum disorders, often presents with acute disseminated encephalomyelitis (ADEM) symptoms in pediatric patients. Appropriate treatment based on accurate diagnosis is challenging in relapsing pediatric patients with MOGAD. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CASE PRESENTATION: An 11-year-old girl experienced relapses four times, exhibiting brainstem symptoms, an ADEM episode, seizures, and optic neuritis (ON). She was initially diagnosed with multiple sclerosis and received interferon beta-1a therapy with a mild effect on relapse suppression. She was then transferred from the pediatric department to the department of neurology of our hospital. Two months before her referral visit, she experienced left optic neuritis, and her annualized relapse rate reached 0.6. She desired to switch from the injectable treatment to oral dimethyl fumarate (DMF) administration. At that time, she was found to be seropositive for MOG antibody, but after that had no relapses for more than five years. Moreover, her seropositivity for serum MOG-antibody turned out to be seronegative. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: DMF showed long-term effects on suppressing relapses in a pediatric patient with MOGAD, revealing its potential as a treatment option for such patients.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40070831/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">40070831</a> | PMC: <a href="https://www.ncbi.nlm.nih.gov/pmc/PMC11893387/?utm_source=Chrome&utm_medium=rss&utm_campaign=journals&utm_content=101560960&ff=20250312141510&v=2.18.0.post9+e462414">PMC11893387</a> | DOI: <a href=https://doi.org/10.3389/fimmu.2025.1551379>10.3389/fimmu.2025.1551379</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:40070831</guid><pubDate> Wed, 12 Mar 2025 06:00:00 -0400</pubDate><dc:creator> Masayuki Tahara</dc:creator><dc:creator> Tomonari Awaya</dc:creator><dc:creator> Keisuke Saito</dc:creator><dc:creator> Hideyuki Sawada</dc:creator><dc:date> 2025-03-12</dc:date><dc:source>免疫学领域</dc:source><dc:title>Case Report: Long-term suppression of relapses by dimethyl fumarate in a relapsing pediatric patient with myelin oligodendrocyte glycoprotein antibody-associated disease manifesting as acute disseminated encephalomyelitis, unilateral optic neuritis, and seizure episodes</dc:title><dc:identifier> pmid:40070831</dc:identifier><dc:identifier> pmc:PMC11893387</dc:identifier><dc:identifier> doi:10.3389/fimmu.2025.1551379</dc:identifier></item></channel></rss>